Addleshaw Goddard has advised Buenavista Equity Partners on the structuring and first closing of a new health fund, BV Healthcare Growth Innvierte I, with investment commitments of €100 million, and with a maximum planned size of €150 million.

The management of this fund is supported by Columbus Venture Partners through a joint venture in which both firms combine investment experience in venture capital, private equity and the health sector. The investment base for this new vehicle is supported by the Centre for Technological Development and Innovation (CDTI), which has made a commitment of up to 58 million euros through its Innvierte Programme.

The fund focuses on investing in innovative companies, mostly Spanish, in the healthcare field, dedicated to the development of pharmaceutical and biotechnological products, diagnostic solutions, precision medicine and medical equipment, AI & Big Data as well as digital therapies and diagnostics, scale-up projects  in industrial production, scientific services (CRO, CDMO) and healthcare services.

Isabel Rodríguez, partner and head of the Funds area of Addleshaw Goddard in Madrid, has been in charge of coordinating the legal advice to Buenavista Equity Partners, together with senior associate Enrique Torné and associate Nemesio Fernández.